RxDoctor Payments Data

Rosalba Mucciarella, MD

Internal Medicine · Williamsville, NYNPI 1497717888

Payments from drug & device makers

$9,374in general payments, 2019–2025

Across 538 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • Novo Nordisk$916
  • Sanofi-aventis U.S. LLC$646
  • Mannkind Corporation$561
  • AbbVie$499
  • Amgen$491
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$9,374100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,374 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$30,990
Medicare patients
86
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$34,835
MounjaroTirzepatide25$33,104
TrulicityDulaglutide24$32,957
EliquisApixaban44$30,475
RybelsusSemaglutide19$26,693
Victoza 3-PakLiraglutide18$14,916
JanuviaSitagliptin Phosphate12$9,735
Levothyroxine Sodium353$8,613
SynthroidLevothyroxine Sodium54$5,549
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$4,786
Rosuvastatin Calcium238$4,400
Atorvastatin Calcium126$1,923
Ibandronate Sodium68$1,897
Metoprolol Succinate103$1,872
Metformin Hcl ErMetformin Hcl63$1,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,880$66,06149 claims
Novo NordiskOzempic, Rybelsus$916$61,52846 claims
PfizerEliquis$232$30,47544 claims
MerckJanuvia$98$9,73512 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$123$8,613353 claims
AbbVieSynthroid$499$5,54954 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →